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Abstract

SYNTHESIS AND CHARACTERIZATION OF DOXORUBICIN CARRYING CETUXIMABPAMAM DENDRIMER BIOCONJUGATES
By Gunjan Saxena

A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Biomedical Engineering at Virginia Commonwealth University
Virginia Commonwealth University, 2012

Director: Hu Yang, Ph.D., Associate Professor, Biomedical Engineering

A tumor targeted dendrimer based drug delivery system was designed and synthesized to
carry chemotherapy drug doxorubicin. Polyamidoamine (PAMAM) dendrimer G4.5 was chosen
as the underlying carrier. Anionic G4.5 is a good option for drug delivery as it consists of 128
surface groups, is less cytotoxic and favorably biodistributed. The delivery system was
synthesized using a layer-by layer arrangement of three functional entities: chemotherapy drug
doxorubicin, monoclonal antibody Cetuximab against EGF receptor, and polyethylene glycol
(PEG). Doxorubicin was attached via an acid-sensitive hydrazon linkage to the dendrimer.
Macromolecules are taken in by cells through endocytosis. pH inside the early endosomes to
lysosomes ranges from pH 6 to 4.5. These acidic conditions are favorable for release of drug
bound to the dendrimer vehicle through acid-sensitive linkage. 35% of all solid tumors of brain
express exceptionally high EGF receptors whereas normal brain tumors express less EGFR. This
makes the EGFR a potent targeting moiety for targeted drug delivery. Cetuximab will serve as a
targeting ligand to help the delivery system target tumor cells. PEG was incorporated as a linker

xi

between Cetuximab and dendrimer to avoid reticuloendothelial system (RES) uptake of the
system, increase biocompatibility, increase drug half-life and other shortcomings associated with
nanomaterials. Nuclear magnetic resonance spectroscopy (NMR), fluorescence anisotropy, and
western blotting were used to confirm the conjugation of PEG, doxorubicin and cetuximab to the
dendrimer. The synthesized delivery system was characterized using ultraviolet-visible
spectroscopy (UV-Vis) to approximate the number of doxorubicin attached. Dynamic light
scattering (DLS) and zeta potential were used to analyze the change in size and surface
properties of dendrimer during the synthesis. Doxorubicin release studies were conducted at
different pHs. Maximum doxorubicin was released at pH 4.5 indicating the successful acidsensitive linkage between the drug and dendrimer. Cytotoxicity studies indicated that the
addition of PEG increased the biocompatibility as compared to free doxorubicin whereas;
combination of doxorubicin and cetuximab exerted a significant toxic effect over a period of 72
hours. The cellular uptake of the delivery system was higher than that of free doxorubicin. Free
DOX localized mainly in the nucleus whereas, CTX-G4.5-PEG-DOX conjugate localized within
both cytoplasm and nucleus after 6 hour incubation. The synthesized delivery system represents
a potential targeted drug delivery system.

xii

CHAPTER 1 INTRODUCTION
According to the World Health Organization (WHO), brain diseases such as epilepsy,
Alzheimer’s disease, cerebrovascular disease, brain cancers are a major healthcare problem
worldwide. Particularly, brain cancer is one of the most complex and deadly diseases known to
human beings. According to the Central Brain Tumor Registry of The United States, over
612,000 people are living with primary brain and central nervous system (CNS) tumor being
diagnosed. It was estimated that 64,530 new patients would be diagnosed with primary nonmalignant and malignant brain tumor in the US alone in 2011 (http://cbtrus.org/factsheet/fact
sheet.html, cited December 3, 2011).
The major factor limiting therapeutic treatment of CNS diseases is the brain’s effective
protective mechanism known as the blood-brain barrier (BBB) (Pardridge et al., 2005). With the
presence of BBB, only 2% of small-molecular-weight drugs pass through, whereas nearly all
large-molecular-weight neurotherapeutics are excluded from the brain (Pardridge et al., 2005).
Thus the treatment efficacy is largely dependent on drug delivery efficiency. Brain drug delivery
routes such as trans-cranial drug delivery, trans-nasal brain drug delivery, and BBB disruption
are invasive, potentially leading to irreversible side effects or allow a very limited distribution of
drug in the brain. Some notable examples are implanting drug eluting wafers after surgical tumor
removal, insertion of catheters for pumping drugs into the brain (Abbott et al., 2004; Pardridge et
al., 2007). Some relatively less invasive delivery systems have been developed to utilize
receptor- targeted delivery mechanism for enhanced brain drug uptake (Yan et al., 2011). In this
approach, drug carriers, particularly nanocarriers, play an important role. Nanocarriers are
unique as they are small in size. They help increase the permeability, half-life, solubility and
stability of the drug in the body. Being the most versatile nanoscale building blocks, dendrimers
1

have received considerable attention. Among them polyamidoamine (PAMAM) dendrimers are
most investigated (Yan et al., 2011; Yang et al., 2010; Lee et al., 2005). As opposed to linear
polymers, dendrimers have highly branched, well-defined architecture with very low
polydispersity (PDI) (Svenson et al., 2009). Furthermore, availability of a number of functional
groups on their periphery can be used for attachment of drugs (Kolhe et al., 2006; Kurtoglu et al.,
2009; Kono et al., 2008), solubilizing groups (Gillies et al., 2005), targeting ligands
(Chandrasekar et al., 2007), or imaging agents (Patri et al., 2004) for efficient drug delivery or
imaging.
In this thesis research, we designed and developed a brain-targeted PEGylated dendrimer
drug delivery system for anticancer drug delivery. Biocompatible polyethylene glycol (PEG) was
incorporated into the system aiming at reducing immunogenicity, minimizing particle
aggregation, improving the carrier’s water solubility, decreasing reticuloendothelial system
(RES) opsonization, and strengthening the enhanced permeability and retention (EPR) effect
(Boswell et al., 2008). Doxorubicin (DOX), an anti-cancer drug, was used as a model drug.
Chimeric monoclonal antibody Cetuximab (CTX) was used as a targeting ligand. It is a 150kDa
IgG1K, produced by Sp2/0 mammalian cell line, against the epidermal growth factor receptor
(EGFR) and its mutant form EGFRvIII over-expressed in 35% of all solid tumors (Lahlou et al.,
2009). The synthesis involved step-by-step assembly of functional groups in sequence including
PEG, DOX, CTX on the surface of PAMAM dendrimer G4.5. Particularly DOX was attached to
the dendrimer via an acid-labile hydrazone linkage. CTX-PEG-G4.5-DOX bioconjugates and
intermediates were characterized using 1H-NMR, fluorescence anisotropy, western blotting,
dynamic light scattering and zeta potential. The cellular uptake and cytotoxicity of the delivery
system was investigated. The in vitro release kinetics of doxorubicin was also studied.
2

CHAPTER 2 BACKGROUND
2.1 Blood brain barrier (BBB)
The brain is a delicate organ, and evolution built very efficient ways to protect it. The
physiological mechanism that alters the permeability of brain capillaries so as to maintain
homeostasis of the brain is collectively referred to as the “blood-brain barrier.” A journey to
understanding of BBB started a century ago. A German bacteriologist, Paul Ehrlich studied
staining of brain in 1885. He observed that dyes did not have a staining affinity to the brain
because intravenously administered aniline dyes stained every organ but the brain (Wells et al.,
2005). In 1913, his student Edwin Goldman experimentally proved that dye could stain brain
tissue but did not reach the brain. Furthermore, he found that dye injected through subarachnoid
space stained cerebrospinal fluid (CSF) but not peripheral tissues. This demonstrated the
existence of the ‘barrier.’ It was not until 1967 and introduction of high resolution microscopy
that Resse and Karnovsky revealed that endothelial cells in mouse cerebral capillaries formed a
structural barrier to horseradish peroxidase (HRP) (Reese and Karnovsky et al., 1967). Thus the
statement that the BBB is “an endothelial barrier present in capillaries that course through the
brain” was made (Rubin et al., 1999).
Although the BBB is an important mechanism to protect the brain, it also represents a
formidable barrier to therapeutics required for treatment of CNS diseases (Abbott et al., 1996).
Nearly 100% large-molecular-weight pharmaceutics such as proteins, peptides, RNA
interference (RNAi)-based drugs have limited transport across the BBB. Only small lipophilic
molecules with molecular weight around or under 400-500 daltons can cross the BBB (Pardridge
et al., 2007). But, these small molecules can only be effective in treating certain CNS diseases
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such as chronic pain, epilepsy and insomnia (Pardridge et al., 2007). The presence of Pglycoprotein on the luminal side of the BBB expels a variety of substances out of the brain to
maintain homeostasis, making drug delivery to the brain even more challenging (Pardridge et al.,
1997; Golden et al., 1999; El Hafny et al., 1997). Transporter proteins or receptors present on the
BBB help essential nutrients such as glucose, amino acids and transferrin to get into the brain
(Pardridge et al., 1997; Abbott et al., 2006). Even with the availability of various transporting
systems on the BBB, no such ‘transporter’ has been successfully used in transporting large
molecules to the brain.
A well accepted BBB model is a three-cell type model. In this model, the BBB comprises
brain capillary endothelial cells, astrocytes and pericytes as shown in Figure 2.1 (Garberg et al.,
2005; Flaten et al., 2006; Pardridge et al., 1999).
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Figure 2.1 Illustration of a cerebral capillary enclosed in astrocyte end-feet (Redrawn from
http://www.answers.com/topic/blood-brain-barrier, cited December 6, 2011)
2.2 Brain tumor
Brain tumor is an intracranial mass produced as a result of an uncontrolled growth of cells
either normally found in the brain such as neurons, lymphatic tissue, blood vessels, or from
cancers primarily located in other organs. Brain tumors can be classified based on whether it is
benign (non cancerous, do not invade or spread to surrounding tissues) or malignant (invasive),
the location of the tumor or the type of tissue involved.
Primary brain tumors are the tumors which originate in the brain. Secondary brain tumors
originate from the tumor cells which spread to brain from another location in the body. These
5

mostly originate from organs like breast, kidney, lungs, renal or from melanomas in the skin
(Sawaya et al., 2001). Primary brain tumor may be associated with edema and necrosis. Edema is
generally found in the white matter regions around the tumor (Prastawa et al., 2005). By
definition, brain edema is an increase in brain volume resulting from increased sodium and water
content and results from local disruption of the blood brain barrier (BBB). Necrosis is composed
of dead cells in the middle of the brain tumor. It is one of the leading causes of mortality
resulting from brain tumors.
Primary brain tumors can be further classified by tissue origin. The major primary brain
tumor types based on tissue origin are summarized in Table 2.1 (CBTRUS, 2002; Doolittle et al.,
2004). On the basis of location tumors can be classified into 3 classes: local tumors, regional
tumors and distant tumors. Local tumors are confined to one hemisphere in part of brain.
Regional tumors are those which cross midline and invade bone, blood vessel, nerves and spinal
cord. Distant tumors can extend up to the nasal cavity, nasopharynx and outside the CNS.
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Table 2.1 Primary brain and CNS tumors by histology and percent reported (Redrawn from
Doolittle, 2004)
Histology

% of Reported Brain Tumors

Tumors of neuroepithelial tissue

48.1

Glioblastoma

23.0

Astrocytoma

4.2

Anaplastic astrocytoma

3.7

Oligodendroglioma

2.9

Glioma malignant

2.7

Others

10.6

Tumors of the meninges

28.7

Meningioma

27.4

Other mesenchymal, benign and malignant

1.2

Lymphomas and hematopoietic neoplasms

2.7

Germ cell tumors and cysts

0.5

Tumors of the sellar region

7.4

Pituitary

6.6

Craniopharyngioma

0.8

Local extensions from regional tumors

0.2

Unclassified tumors

5.0

Hemangioma

0.4

Neoplasm, unspecified

4.5

Other

0.1

Total

100.0
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2.3 Conventional and modern treatments
Brain tumors can be treated by various methods including surgery, radiation therapy,
chemotherapy, and drug delivery. In this section, conventional and modern treatment strategies
for the treatment of brain tumors are discussed briefly.
2.3.1 Surgery
Surgery is usually the first step in brain tumor treatment. It is preferred to remove as much
tumor as possible and to reduce the intracranial pressure. Surgical removal of brain tumors is
expected to control tumor-induced seizures and is a necessary step before radiation and
chemotherapy. Some tumors are difficult to resect when they are located at an inaccessible site
such as brain stem and thalamus. If a large number of tumors are present or if their borders or
edges are poorly defined, it will be more challenging for safe removal. Many other factors such
as patient’s general health, neurological status, and history of recovery from surgery should be
taken into consideration and can hinder surgery as an option for tumor removal (American Brain
Tumor Association. Surgery Brochure, 2004).
Surgery poses both general and specific risks. Common risks include infection, bleeding,
blood clots, pneumonia and blood pressure instability. In addition, partial or complete loss of
sensation, vision, movement, hearing or other functions are the possible consequences of
surgery. Surgery on brain tumors located deep inside the brain is more challenging and
potentially causes more serious side effects including seizures, weakness, spinal fluid leakage,
brain swelling, stroke, coma, and even death (American Brain Tumor Association, Surgery
Brochure, 2008). There are many different types of surgery for brain tumors as summarized in
Table 2.2.
8

Table 2.2 Types of surgery with their procedure and purpose (based on American Brain Tumor
Association, Surgery Brochure, 2008)

Type of Surgery

Procedure and Purpose

Biopsy

To obtain tissue sample for pathology

Needle biopsy
Stereotactic biopsy

Hole drilled into skull, sample tissue drawn up by
hollow needle
Computer-assisted needle biopsy

Open biopsy

Tissue sample taken during surgery

Craniotomy

Opening and removing a part of skull for surgery and
replacement of removed skull

Craniectomy

Similar to craniotomy with bone not being replaced
before closing incision

Debulking

Surgically reduce size of tumor

Partial removal

Partial removal of tumor, requires additional treatment

Complete removal

Gross total resection, tumor cells might remain

Shunt

Remove excess fluid, reduces intracranial pressure

Ommaya Reservior

Implanted container used to deliver chemotherapy,
remove CSF and cystic fluid

Skull base

Special technique to remove tumors in delicate bony
area that supports the bottom of the brain

Transphenoidal

Incision is under the upper lip and over the teeth, or
directly through the nostril

2.3.2 Radiation therapy
The purpose of radiation therapy is to control or prevent brain tumor growth. Radiation
therapy is often used after surgery to treat inoperable tumors or metastatic tumors. It can also be
applied during or after chemotherapy or along with drugs that make tumor cells more sensitive to
radiation. In principle, radiation (x-rays, gamma rays, or photons) either kill tumor cells directly
or interferes with their ability to grow (American Brain Tumor Association. Radiation therapy
Brochure, 2004). Normal brain tissue can tolerate up to 60 Gy (Gray units) of radiation per dose,
different tumors require different doses of radiation. For example, glioblastoma (GB), typically
9

receive 180-200 cGy (centi-Gray units) per dose, 5 days a week for 6 weeks, totaling 5400-6000
cGy over the course of radiation therapy (Castro et al., 2003; American Brain Tumor
Association, Radiation therapy Brochure, 2009). Like any other radiation treatment, brain tumor
radiation causes side effects including fatigue, hair loss, changes in skin, swelling, nausea, sexual
effects, blood clots and post-treatment depression.
2.3.3 Chemotherapy
Chemotherapy is the method to treat benign or malignant brain tumors with the use of drugs.
There are different types of chemotherapy drugs available such as drugs that stop cells from
starting the cycle, “targeted or biological agents”, and that which act during a particular phase of
cell cycle, “cell-cycle specific” drugs. There are also some “non cell-cycle specific drugs” which
are not cycle dependent. Chemotherapy drugs can be delivered to the body via systemic or local
delivery. Systemic delivery is where the drug is administered orally or injected into the body and
circulates via bloodstream before it crosses the BBB and enters the brain. Local delivery places
the drug within or near the tumor in the brain. This produces a higher concentration of drug at
the tumor site and minimizes toxic effects on normal cells. Chemotherapy drugs are classified
into two types - cytotoxic drugs causing cell death and cytostatic agents preventing cell division
(American Brain Tumor Association. Chemotherapy Brochure, 2004). The subgroups of each
type are summarized in Figure 2.2.

10

Figure 2.2 Classification of chemotherapy drugs (based on American Brain Tumor Association,
Chemotherapy Brochure, 2009)
Anti-tumor antibiotics stop the activity of enzymes needed for cell growth. One example is an
anthracycline antibiotic, doxorubicin (DOX) (Figure 2.3). It is closely related to the natural
product daunomycin. It intercalates with DNA (Beer et al., 2001) and stops the macromolecular
biosynthesis (Fornari et al., 1994; Momparler et al., 1976). Topoisomerase II relaxes the DNA
supercoils, after which DOX stabilizes the topoisomerase II complex thus inhibiting
transcription. The aromatic portion of DOX intercalates with the base pairs of the DNA, whereas
daunosamine sugar interacts with base pairs adjacent to intercalation site (Frederick et al., 1990;
Pigram et al., 1972).
11

Figure 2.3 Structure of doxorubicin (Redrawn from DrugBank)
The side effects of chemotherapy are closely related to the type of drug used. Common side
effects include nausea, vomiting, sores in the mouth and throat, loss of appetite, diarrhea
dizziness, hair loss and fatigue. Serious side effects include hives, skin rash, itching, difficulty
breathing or swallowing, seizures, heart arrhythmias and neutropenia (decrease in white blood
cells) (Castro et al., 2003; American Brain Tumor Society, Chemotherapy Brochure, 2009).
Chemotherapy drugs can be delivered to the brain via different routes such as BBB disruption,
blood or marrow stem cell transplantation, convention enhanced delivery (CED), high dose
chemotherapy, intracavitary/ polymer wafer implants, interstitial therapies and reservoirs and
pumps (American Brain tumor Society, Chemotherapy Brochure, 2009). Not all of the methods
mentioned above have been adopted as standard methods.
2.3.4 Drug delivery
Nanotechnology and polymers have been applied to develop efficient and novel drug
delivery systems. Some delivery strategies are shown in Table 2.3 (Jain et al., 2005).
12

Particularly, nanoparticulate drug delivery systems have drawn considerable attention. A variety
of materials such as linear polymers, hyperbranched polymers, micelles, dendrimers and lipids
can be used to make nanoparticulate drug delivery systems (Kwangjae et al., 2008).
2.3.4.1 Polymer-based drug carriers
Drugs can be either physically encapsulated or covalently conjugated to polymers (Rawat et
al., 2006). Both natural and synthetic polymers have been used in drug delivery.
2.3.4.1.1 Polymeric nanoparticles
Albumin, chitosan and heparin are naturally occurring polymers, and they have been used to
deliver drugs eg. Albumin-bound-paclitaxel (Abraxane) for metastatic breast cancer (Gradishar
et al., 2005), non-small-cell lung cancer (phase II trial; Green et al., 2006) and nonhematologic
malignancies (phase I, pharmacokinetics trials; Nyman et al., 2005). Side effects of
chemotherapy drugs can be reduced through conjugation with synthetic polymers such as
polymer poly-L-glutamic acid (PGA) and N-(2-hydroxypropyl)-methacrylamide copolymer
(HPMA) (Li et al., 2002). PGA conjugated with taxol (Xyotax, Sabbatini et al., 2004) and with
camptothecin (CT-2106, Bhatt et al., 2003) is in clinical trials. DOX conjugated with HPMA
(PK1) is in clinical trial for treating a variety of tumors (Vasey et al., 1999). Recently, DOX
conjugated with HPMA (HPMA-DOX, PK1) was further conjugated to galactosamine (HPMADOX-galactosamine, PK2) and has cleared Phase I/II trials (Seymour et al., 2002) as mentioned
in Table 2.4.
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Table 2.3 Drug delivery strategies in cancer (Redrawn from Jain et al., 2005)












































Direct introduction of drug
Direct injection into tumor
Tumor necrosis therapy
Local injection for radio-potentiating
Electro-chemotherapy
Local delivery by implants
Routes of drug delivery
Intraperitoneal
Intrathecal
Nasal
Oral
Subcutaneous injection/ implant
Trans-dermal drug delivery
Intravenous, intra-arterial vascular route
Systemic targeted delivery
Heat-activated
Tissue-selective using carrier-mediated transport systems
Tumor-activated drug therapy
Pressure-induced filtration of drug across vessels to tumors
Two-step targeting using bi-specific antibody
Site-specific delivery
Light-activation
Targeted to blood vessels of tumor
Antiangiogenesis therapy
Angiolytic therapy
Induce clotting
Vascular targeting agents
Special formulations and carriers
Albumin-based carriers
Carbohydrate-enhanced chemotherapy
Protein and peptide delivery
Fatty acids as targeting vectors
Microspheres
Monoclonal antibodies
Nanoparticles
Pegylated liposomes
PEG technology
Single-chain antigen-binding technology
Trans-membrane drug delivery to intracellular targets
Cytoporter
Receptor-mediated endocytosis
Transduction of proteins and peptides
Vitamins as carriers
Biological therapies
Antisense therapy
Cell therapy
Gene therapy
Genetically modified bacteria
Oncolytic viruses
RNA interference
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Table 2.4 Nanocarriers for drug delivery (Redrawn from Kwangjae et al., 2008)
System
Polymeric
nanoparticles

Structure
Drug conjugated to
the polymer via
cleavable linker

Characteristics
 Hydrophilic, nontoxic,
biodegradable
 Possibility of surface modification
(PEGylation)
 Selective accumulation and
retention in tumor tissue
 Specific targeting of cancer cells

Examples
 Albumin-Taxol, Abraxane
(Gradishar, 2005)
 PGA-Taxol, Xyotax
(Sabbatini, 2004)
 PGA-Camptothecin, CT2106 (Bhatt, 2003)
 HPMA-DOX, PK1
(Vasey, 1999)
 HPMA-DOXgalactosamine, PK2
(Seymour, 2002)

Polymeric
micelles

Amphiphilic
block
copolymers assemble
to form hydrophobic
core and hydrophilic
shell micelles

 Carriers for hydrophobic drugs
 Biodegradable, biocompatible, selfassembling
 Functional modification
 Targeting potential

 PEG-pluronic-DOX
(Batrakova, 1996)
 PEG-PAA-DOX, NK911
(Nakanishi, 2001)
 PEG-PLA-Taxol,
Genexol-PM (Kim, 2004)

Dendrimers

Systematic
hyperbranched
polymer with radially
emerging pattern and
repeated units

 Tuning of biodistribution and PK
 Chemical and structural
homogeneity
 Easy functionality and high ligand
density
 Controlled degradation
 Multifunctional

 PAMAM-MTX
(Kukowska, 2005)
 PAMAM-platinate (Malik,
1999)

Liposomes

Lipid bilayers forming
self-assembled closed
colloidal structures

 Targeting potential
 Easy modification
 Biocompatible, Amphiphilic

 PEGylated liposomal
DOX, Doxil (Markman,
2006)
 Non-PEGylated liposomal
DOX, Myocet (Rivera,
2003)
 Liposomal daunorubicin,
DaunoXome (Rosenthal,
2002)

Viral
nanoparticles

Multivalent selfassembled protein
cages

 Modified surface by mutagenesis or
bioconjugation
 Tumor targeting
 Uniformity and defined structure
 Inert and biocompatible

 HSP-DOX (Flenniken,
2006, 2005)
 CPMV-DOX
(Manchester, 2006)

Carbon
nanotubes

Carbon cylinder
consisting benzene
ring

 Hydrophilic, biocompatible
 Multifunctional

 CNT-MTX (Pastorin,
2006)
 CNT-amphotericin B
(Wu,2005)
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2.3.4.1.2 Polymeric micelles (amphiphilic block copolymers)
Micelles are made of amphiphilic block copolymers. These blocks form nanosized core/shell
structures with a hydrophobic core and a hydrophilic shell in an aqueous media. The
hydrophobic core helps with encapsulation of hydrophobic drugs (Adams et al., 2003).
Polymeric micelle formulations of paclitaxel are in phase I and pharmacokinetic studies for
patients with refractory malignancies as mentioned in Table 2.4 (Kim et al., 2004). MRIultrasensitive imaging agents carrying multi-functional micelles have also been developed
(Nasongkla et al., 2006).
2.3.4.1.3 Dendrimers
Tomalia et. al. developed a class of nanoscale, highly branched, synthetic polymeric
macromolecule known as dendrimers (Tomalia et al., 1985). Dendrimers have received
significant attention for drug delivery because of its diverse properties: monodisperse size,
modifiable surface functionality, multivalency, water solubility, hollow core and low
polydispersity (Klajnert et al., 2007; Svenson et al., 2005). Polyamidoamine (PAMAM)
dendrimers, most widely used for drug delivery, have either an ethylenediamine (EDA) or an
ammonia core with methyl acrylate and ethylene diamine branches (Klajnert et al., 2007;
Tomalia et al., 1985). They are commercially available as full generation (cationic) having amine
terminal groups and half generations (anionic) having carboxyl terminal groups (Klajnert et al.,
2007). PAMAM dendrimer has been conjugated with cisplatin for sarcomas (Malik et al., 1999)
and methotrexate (MTX) on animal models for epithelial cancer (Kukowska-Latallo et al., 2005)
as mentioned in Table 2.4.
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2.3.4.2 Lipid-based drug carriers
Liposomes are closed colloidal structures made of self-assembled lipid bilayers. They have a
spherical structure having a hydrophilic core. Many chemotherapeutic drugs can be delivered by
liposomes. As summarized in Table 2.4, a few lipid formulations carrying DOX have been
approved by FDA, e.g. Doxil (Markman et al., 2006) for treatment of ovarian cancer, Myocet
(Rivera et al., 2003) for treatment of metastatic breast cancer and with daunorubicin such as
DaunoXome (Rosenthal et al., 2002) for treatment of AIDS-related Kaposi’s sarcoma (Markman
et al., 2006; Rivera et al., 2003; Rosenthal et al., 2002).
2.3.4.3 Viral nanoparticles
Researchers have developed virus-based vehicles such as mosaic virus, canine parvovirus for
tissue and drug targeting. Specific in vivo tumor targeting has been achieved by conjugating
ligands or antibodies such as transferrin, folic acid to viruses (Manchester et al., 2006). Canine
parvovirus has a natural affinity for transferrin receptor up-regulated in tumor cells (Singh et al.,
2006) as summarized in Table 2.4.
2.3.4.4 Carbon nanotubes
Carbon nanotubes are cylindrical structures made of benzene rings (Bianco et al., 2005).
Carbon nanotubes have found applications for detection of DNA (Cai et al., 2003; Wang et al.,
2004; Williams et al., 2002), discrimination of protein (Gooding et al., 2003; Wang et al., 2004),
ion channel blockers (Park et al., 2003), and drug/ vaccine delivery (Bianco et al., 2005).
However, carbon nanotubes have low water solubility and can cause toxicity. Surface
modification can improve their water solubility and biocompatibility (Bianco et al., 2005). In
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vitro studies involving carbon nanotubes have been promising for drug delivery (Wu et al., 2005;
Pastorin et al., 2006). Presence of multiple functionalities on the sidewalls allows them to carry
different molecules e.g., drugs and fluorescent agents (Pastorin et al., 2006) at once, thus
providing a fundamental advantage for cancer treatment. Methotrexate (Pastorin et al., 2006) and
amphotericin B (Wu et al., 2005) that were conjugated to carbon nanotubes showed more
efficient cellular internalization compared to free drug.
2.3.4.5 Drug delivery using monoclonal antibodies
Monoclonal antibodies (MAb’s) can function as diagnostic agent and/or therapeutic agent
(Jain et al., 2005). Several MAb’s have been approved by FDA for cancer treatment. For
example, Cetuximab (Erbitux, CTX) is a chimeric monoclonal antibody of immunoglobulin G1
class, against the human epidermal growth factor receptor (EGFR) (Baselga et al., 2001;
Goldstein et al., 1995; FDA, 2004). CTX has been recently approved by the FDA as an anticancer agent for colorectal (FDA, 2004) and head & neck cancers (FDA, 2011). EGFR is over
expressed in more than 35% of all solid malignant tumors (Salomon et al., 1995). EGFR is one
of the members of the erbB family of receptor tyrosine kinases. It can be divided into an
extracellular domain that can bind ligands, a trans-membrane domain and an intracellular
tyrosine kinase domain (Yarden et al., 2001). When a ligand binds to EGFR, it causes receptor
dimerization leading to tyrosine kinase activation and receptor autophosphorylation which in
turn initiates signal-transduction pathways. These pathways are involved in proliferation and
survival of cell (Yarden et al., 2001). CTX competitively binds to EGFR and blocks the binding
site of ligand. This inhibits dimerization & receptor phosphorylation, thus stopping downstream
signaling pathway (Kirkpatrick et al., 2004). The EGFR working mechanism and CTX blocking
is mentioned in Figure 2.4.
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Figure 2.4 Schematic diagram representing mode of action of EGFR and CTX (Redrawn from
Kirkpatrick et al., 2004)
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CHAPTER 3 MATERIALS AND METHODS
3.1 Materials and reagents
Table 3.1 List of materials and reagents used
Material

Abbreviation

Source

Polyamidoamine dendrimer generation 4.5

G4.5

Sigma Aldrich

N-hydrosuccinimide

NHS

Fluka

1-ethyl-3-(3-dimethylaminopropyl)

EDC

Sigma Aldrich

Amine Polyethylene glycol-maleimide

NH2-PEG-mal

Jen-Kem

N-methylmorpholine

NMM

Acros

N,N-dimethylformamide

DMF

Sigma Aldrich

Isobutyl chloroformate

IBCF

Acros

Carbazic acid-tert-butyl ester

Cat-BE

Sigma Aldrich

Doxorubicin

DOX

Sigma Aldrich

Trifluoroacetic acid

TFA

Sigma Aldrich

Methanol

MeOH

Sigma Aldrich

Cetuximab

CTX

Gifted from Dr. Michael H. Peters’s Lab,

carbodiimide)

Chemical and Life Science Engineering, VCU
Traut’s reagent

Thermo Scientific

De-ionized water

DI water

Diethyl ether

Ether

EMD Chemicals

Sodium bicarbonate solution

NaHCO3

Sigma Aldrich

Phosphate buffer saline

PBS

Sigma Aldrich
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3.2 Equipment
Table 3.2 List of equipment and machines used
Equipment name

Use

Rotary evaporator, Heidolph LABOROTA 4000

Distillation of low boiling point chemicals from mixture of
compounds

Flexi-dry MP controlled rate freezer, FTS Systems,

Freeze drying the samples

Inc.
Weighing scale

Measuring quantity of chemicals

Eppendorf centrifuge model-5415D

Density based separation of compounds in a mixture

Bruker AVANCEIII 600 MHz, Nuclear Magnetic

Measuring chemical shifts of protons, 1H-NMR

Resonance (NMR) spectrometer
Malvern’s Zetasizer Nano ZS90

Measurement of hydrodynamic radius and molecular
weight of nanoparticle and electrokinetic potential in
colloidal system

Genesys 6 UV-Vis spectrophotometer

Quantitative analysis of drug release study and gel
filtration chromatography

Zeiss Invertoskop 40C Microscope

Examining cell growth and for cell counting

Nexcelom Bioscience Cellometer ® Auto T4

Automated cell counting

Zeiss Axiovert 200 M fluorescence microscope

Examining of cellular uptake

Beckman Coulter DU® 640 Spectrophotometer

Measurement of protein content in cell lysis studies

Incubator

Temperature and humidity control of cell culture
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3.3 Experimental methods
3.3.1 Preparation of maleimide bearing PEGylated G4.5 dendrimer (mal-PEG-G4.5)
Maleimide bearing PEGylated PAMAM dendrimer G4.5 (mal-PEG-G4.5) was synthesized
by substituting the carboxyl group present on G4.5 PAMAM dendrimer (MW = 26258 dalton)
with NH2-PEG-mal (MW = 3500 dalton) group as described in a previously reported method
(Yang et al., 2003). As shown in Figure 3.1, after removal of methanol from G4.5 stock solution
by rotary evaporation, 0.5 µmol of G4.5 was dissolved in 2ml of DMF. To this solution, 12.8
µmol of EDC and 12.8 µmol of NHS at the feed molar ratio of 25.6:25.6:1 for EDC: NHS: G4.5;
(20% w.r.t. G4.5) was added. After an overnight reaction while stirring at room temperature, the
resultant G4.5-NHS was precipitated in excess amount of cold diethyl ether. The precipitate was
re-dissolved in DI water and then rotary evaporated to obtain G4.5-NHS. The obtained G4.5NHS and NH2-PEG-mal (2 µmol) were dissolved in 2ml and 1ml of 0.1 M NaHCO3 solution (pH
8.5) respectively. NH2-PEG-mal containing NaHCO3 solution was dropwise added to the G4.5NHS solution. The mixture was stirred for 3-4 hours at room temperature and the resulting
conjugates were dialyzed in DI water using dialysis cassette of MWCO 10K. The purified
solution was dried using rotary evaporator to obtain mal-PEG-G4.5.
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Figure 3.1 Preparation of mal-PEG-G4.5
3.3.2 Conjugation of doxorubicin to G4.5-PEG-mal
DOX was covalently attached to the remaining carboxyl groups on the dendrimer surface of
G4.5-PEG-mal. The polymer-DOX conjugates via acid sensitive hydrazone linkage was
synthesized as previously reported (Bae et al., 2003; Lai et al., 2007)
As shown in Figure 3.2, 54.4µmol of Cat-BE at a feed molar ratio of Cat-BE: G4.5 as 1:1
(85% of G4.5) and G4.5-PEG-mal were dissolved in 5ml of DMF respectively. 272 µmol of
NMM was added to G4.5-PEG-mal solution (5 times of 85% of G4.5 molar quantity). 272 µmol
of IBCF (5 times of 85% of G4.5 molar quantity) was added dropwise at 4°C and the mixture
was kept for five minutes was added. After this the Cat-BE solution was added dropwise to this
solution. The mixture was allowed to react for thirty minutes at 4°C and two more hours at room
temperature.
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The white sediments of the by-product formed were removed by centrifuging the solution for
10 minutes at 10,000 rpm. The supernatant was added dropwise to diethyl ether and kept at -20
°C overnight. The precipitate was collected by centrifuging the ether solution for 10 minutes at
10,000 rpm and then re-dissolved in 3ml of PBS (pH 7.4). The product was purified in PBS (pH
7.4) using a dialysis cassette of MWCO 10K. mal-PEG-G4.5-hyd-BOC was obtained after rotary
evaporating the solution. The synthesized mal-PEG-G4.5-hyd-BOC was further treated with 1ml
trifluoro acetic acid (TFA) to remove the BOC protective groups. An excess amount of DOX
(65.28 µmol) was added in 20ml of methanol with TFA as an acid catalyst. The solution was
stirred for 24 hours in dark. The solution was further concentrated to 2ml and then dialyzed in
PBS (pH 7.4) with a dialysis cassette MWCO 7K. The product was further purified using a PD10 desalting column. The purified product was obtained after rotary evaporation.
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Figure 3.2 Conjugation of DOX to G4.5-PEG-mal via hydrazon linkage
3.3.3 Conjugation of Cetuximab to mal-PEG-G4.5-DOX
CTX was thiolated using a similar procedure reported earlier for anti-rat transferrin receptor
OX26 mAb (Huwyler et al., 1996). According to Figure 3.3, 0.06 nmol CTX was dissolved in
0.15 M sodium borate buffer/ 0.1 mM EDTA (pH 8.5) with 2.4 nmol of 2-iminothiolane, Traut’s
reagent (2-iminothiolane : CTX molar ratio 40:1) for 60 minutes in dark at room temperature.
Afterwards, 0.03 nmol mal-PEG-G4.5-DOX was added to the thiolated CTX mixture to react
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overnight with gentle shaking. The mixture was concentrated using a rotary evaporator and
purified using Sephacryl S-200 HR column.

Figure 3.3 Conjugation of CTX to mal-PEG-G4.5-DOX
3.4 Characterization
3.4.1 Proton nuclear magnetic resonance spectroscopy (1H-NMR)
1

H-NMR spectroscopy was performed on Brucker AVANCE III 600 MHz NMR

spectrometer with D2O as the solvent. The data obtained was processed using MestReNova
NMR software (licensed software) from Mestrelab research. The chemical shift of D2O residue
was observed at 4.8 ppm.
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3.4.2 Fluorescence anisotropy
Anisotropy was performed to confirm the conjugation of doxorubicin to mal-PEG-G4.5.
Doxorubicin is a fluorescent molecule. Fluorescent molecules when struck with polarized light
result in polarized fluorescence (Ingersoll et al., 2007). The rotational diffusion of the
fluorophore during the excited lifetime is the main cause of this depolarized fluorescence. Thus
by measuring these fluorescence polarizations, the rotational mobility of the fluorophore can be
easily determined. Anisotropy is the technique to experimentally find out fluorescence
depolarization. It is directly related to the polarized-light component and inversely to total light
intensity.

A schematic diagram representing basic “L-format” fluorescence polarization is

shown in Figure 3.4. The sample is first excited using a vertically polarized light and thus the
intensity component with both excitation and emission polarizer mounted vertically (IVV) and
intensity component with excitation polarizer vertical and emission polarizer horizontal (IVH) are
measured.
Anisotropy (r) is given as (Lackowicz et al., 2006)

r

IVV  G * IVH
IVV  2 * G * IVH

Eq. 1

where G, “G-factor” is the ratio of the intensity component with excitation polarizer horizontal
and emission polarizer vertical (IHV) to intensity component with both excitation and emission
polarizers mounted horizontally (IHH).

G=

I HV
I HH

Eq. 2
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It is dependent on the slit width as well as the monochromator wavelength.
Polarization, P can be found out using
P=

3r
2r

Eq. 3

Samples of both free doxorubicin, 0.01 mg, and mal-PEG-G4.5 bound doxorubicin, 0.01 mg
equivalent doxorubicin, were prepared in 1 ml of methanol. The measurements were made using
a Cary Eclipse Fluorescence spectrophotometer equipped with an 80 Hz Xenon arc lamp, R928
detector and was operated at 600V. The maximum excitation was found at a wavelength of 480
nm with maximum emission at a wavelength of 585 nm at room temperature.
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Light source

V
H

Excitation beam
Excitation polarizer
Sample

V
Fluorescence emission

H

Emission polarizer
Detector

Figure 3.4 Schematic representation of “L-format” fluorescence polarization with vertical (V)
and horizontal (H) orientations of polarizer (Redrawn from Ingersoll et al., 2007).

3.4.3 Ultraviolet-visible spectroscopy (UV-Vis)
UV-Vis spectroscopy was performed to calculate the amount of DOX attached to mal-PEGG4.5. DOX stock solution was prepared by dissolving 1 mg of DOX in 1 ml of 1X PBS (pH 7.4).
Five serial dilutions; 1, 0.5, 0.25, 0.125 and 0.062 mg/ml, were prepared to generate a standard
curve, given in Figure 3.5, using a Genesys 6 UV-Vis spectrophotometer. 1.7 mg of mal-PEG-
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G4.5-DOX was dissolved in 1 ml of 1X PBS. The absorbance of this mixture was measured at
480 nm. The absorbance value of mal-PEG-G4.5-DOX was compared to the standard curve of
DOX. The amount of DOX conjugated was calculated as follows. Using the absorbance (A)
determined by UV-Vis spectrophotometer and the equation of line obtained from standard curve,
the concentration of DOX was calculated, which gave the amount of DOX in the mal-PEG-G4.5DOX sample by
Concentration of DOX mg / ml  =

Amount of DOX (mg )
Amount of solution (ml)

Eq. 4

This amount of DOX in mg was converted to amount in moles by
Amount of DOX (mol) =

Amount of DOX (mg )
Molecular Weight of DOX (mg / mol)

Eq. 5

where, molecular weight (MW) of DOX = 580 g/mol. Amount of mal-PEG-G4.5 in sample was
calculated as,
Amount of mal-PEG-G4.5 (mg) = Amount of sample (mg) – Amount of DOX (mg)

Amount of mal-PEG-G4.5 (mol) =

Amount of mal  PEG  G 4.5 (mg )
MW of mal  PEG  G 4.5 (mg / mol)

Eq. 6

Eq. 7

The amount of DOX attached to mal-PEG-G4.5 was calculated as a molar ratio,

Amount of DOX (mol)
Amount of mal  PEG  G 4.5 (mol)

Eq. 8

The same standard curve and UV-Vis spectroscopy was later used for analyzing doxorubicin
release kinetics from the G4.5-DOX conjugate.
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Figure 3.5 Standard curve of DOX
3.4.4 Western blotting
Western blotting is widely used to detect expression of specific protein based on size
separation under gel electrophoresis. The protein sample is dissolved in sodium dodecyl sulphate
(SDS) buffer. SDS buffer is an anionic detergent, which quantitatively binds to proteins. This
binding gives them linearity and a uniform charge, thus they can be separated only based on size
(Burnette et al., 1981). Addition of mercaptorethanol in the buffer reduces any disulphide bonds
within the protein. Western blotting can also be used to approximate the molecular weight of a
protein or a protein conjugate. Samples are loaded into wells in the running gel. One lane
generally contains MW markers, a mixture of proteins of defined molecular weights. Analysis of
the molecular weight is done after electroblotting the separated protein onto a nitrocellulose or
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polyvinylidene difluoride membrane and then photographed. Size approximations are done by
referencing the bands of proteins to those of the marker (Burnette et al., 1981).
To confirm the coupling of CTX to mal-PEG-G4.5-DOX, western blotting was performed.
Free CTX and CTX-PEG-G4.5-DOX containing CTX equivalent concentration of 10 nmol were
dissolved in 20 µl PBS buffer. This mixture was then dissolved in 6X SDS sample loading buffer
(375 mM Tris, pH 6.8, 10% SDS, 50% Glycerol, 10% B-mercaptoethanol, 0.03% Bromophenol
Blue). Protein samples were run on 8% Tris/ Glycine SDS-polyacrylamide gel (120 minutes, 120
V, room temperature). The proteins were electroblotted using 1X- transfer buffer with 20%
methanol (5 mA, overnight, room temperature) on to a polyvinylidene difluoride (PVDF)
membrane (Immobilon-P; Millipore, Billerica, MA) . The membrane was blocked for unspecific
binding with 5% non-fat dry milk (1h, room temperature) in Tris-buffered saline. Then,
membranes were incubated (1h, room temperature) in blocking buffer with IgE antibodies
against cetuximab (1:1000 dilutions). After washing in TTBS, cetuximab were detected using
Western Lightning Enhanced Chemiluminescence (ECL; Perkin-Elmer, Waltham, MA).
3.4.5 Size and zeta potential measurements
Molecules in suspension undergo Brownian motion. When such molecules are illuminated
with a light source, laser in this case, depending on the size of the particles, the intensity of the
scattered light fluctuates (http://www.malvern.com/labeng/technology/dynamic_light_scattering
/dynamic_light_scattering.htm, January 19, 2012).
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The velocity of Brownian motion is calculated using these intensity fluctuations and hence
the hydrodynamic diameter, dH, is calculated using the Stokes-Einstein equation

dH 

kT
3D

Eq. 9

where, k is the Boltzmann constant, T is the temperature, η is the absolute zero-shear viscosity of
the medium and D is the diffusion coefficient (Berne et al., 2000).
Particles in aqueous systems generally acquire a surface charge which can be either by
surface group ionization or charged species adsorption (http://www.malvern.com/labeng/technol
ogy/zeta_potential/zeta_potential_LDE.htm, January 19, 2012). The liquid layer exists in two
parts around the diffused particle; an inner region of strongly bound ions (Stern layer) and an
outer of loosely bound ions (Diffuse layer). The ions and particles move within the boundary of
the diffuse layer. When the particle moves due to Brownian motion, the ions move with it. The
point in this layer where the potential moves past the bulk solution is called the zeta potential. A
schematic representation of zeta potential is shown in Figure 3.6.
An electric field is applied across the dispersion medium in order to measure zeta potential.
The particles in the dispersion will move towards the oppositely charged electrode with a
velocity proportional to the magnitude of the zeta potential. The velocity is measured by laser
Doppler anemometry. As these particles are moving they cause a phase shift of the incident laser,
which is measured as particle mobility. With the use of dispersant viscosity and use of
Smoluchowski or Huckel theory, this mobility is converted to zeta potential (Smoluchowski et
al., 1903).
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Dynamic light scattering (DLS) and zeta potential studies were conducted using a Zetasizer
Nano ZS90 equipped with a He-Ne laser from Malvern Instruments (Saovapakhiran et al., 2009).
The hydrodynamic radius and zeta potential of G4.5 PAMAM dendrimer and the synthesized
products including mal-PEG-G4.5 and mal-PEG-G4.5-DOX were determined. 1X PBS was used
as the solvent and filtered through Whatman- Anotop 25 plus, 0.02 μm syringe filter. Samples
were prepared by dissolving 1 mg of G4.5, 1 mg of mal-PEG-G4.5 and 1 mg of mal-PEG-G4.5DOX each in 1 ml of PBS and vortexed for proper mixing. All measurements were taken at
37˚C.

Figure 3.6 Schematic representation of zeta potential (redrawn from http://www.malvern.com/
labeng/technology/zeta_potential/zeta_potential_LDE.htm, January 19, 2012)
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3.4.6 DOX release studies
The release of DOX from G4.5-DOX was studied at different pHs. 10 mg of CTX-PEGG4.5-DOX in 10 ml of PBS (pH 7.4, 37°C) was sealed in a dialysis bag (MWCO 1000). The
dialysis bag was then submerged in 30 ml of PBS (pH 7.4) in a capped glass bottle and was
incubated at 37°C for 192 hours. The released DOX in the incubation buffer was analyzed at predetermined time intervals up to 192 hours. At every time point, 1 ml aliquot of incubation buffer
was transferred to a micro-centrifuge tube for doxorubicin content analysis. 1 ml of fresh PBS
(pH 7.4) was added to the glass bottle to maintain the volume of incubation buffer. The same
procedure was repeated for drug release studies at pH 4.5 and pH 5.5. Doxorubicin was
quantified using a UV-Vis spectrophotometer at 480 nm. The standard curve of doxorubicin
(Figure 3.5) was used as a reference to calculate the concentration of doxorubicin in each aliquot.
Cumulative release of doxorubicin released was calculated as follows:
n 1
Ct  30 ml   Ct  1ml
n
i
i 1
 100
% Cumulative release (t) =
W
0

Eq. 10

where, Ctn is drug concentration in release medium at time t and W0 is initial amount of DOX in
the sample (mg).
3.4.7 Cell culture
HN12 cells derived from metastatic squamous cell carcinoma were obtained from Dr.
Andrew Yeudall’s lab, School of Dentistry, VCU. HN12 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10 % fetal bovine serum (FBS) and
penicillin-streptomycin (100 units/ml). Cells were grown at 37˚C in a humidified atmosphere
containing 10% CO2 (Yeudall et al., 1994).
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3.4.8 Cytotoxicity assay
Cytotoxicity of CTX-PEG-G4.5-DOX conjugates was evaluated. HN12 cells were seeded in
a twenty-four-well cell culture plate at a density of 5x103 cells/well. After 24 hours of culture,
CTX-PEG-G4.5-DOX conjugates and free DOX at DOX equivalent concentrations of (100, 10
and 1 nmol) were added. The cell viability was assessed in triplicates at 24, 48 and 72h
respectively with the Trypan blue exclusion assay (Strober et al., 2001). The cells were counted
using a Nexcelom Biosciences, Cellometer Auto T4 Cell Counter.
3.4.9 DOX uptake studies
HN12 cells were seeded at a density of 5x103 cells/well in a twenty-four-well cell culture
plate or on a 18 mm-diameter glass cover slip positioned in a twelve-well cell culture plate for
fluorescence imaging. After 24 hour culture at 37°C, free DOX and CTX-PEG-G4.5-DOX
conjugates at DOX equivalent concentration of 10 nmol were added to the wells. Cells were
incubated for 6 hours, after which they were washed twice with ice cold 1X DPBS buffer. The
cells treated with free DOX or CTX-PEG-G4.5-DOX were then fixed to the cover slip with
100% methanol. After adding DAPI (50µg/ml, diluted to 1:4000) the cover slip was mounted on
a glass slide using Vectashield H-1000 mounting medium and fixed with transparent nail polish.
The cover slip was examined with a Zeiss Axiovert 200M inverted microscope at the VCU
Philips Institute of Oral and Craniofacial Molecular Biology at VCU School of Dentistry. Image
analysis was performed using Carl Zeiss Imaging Systems software.
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For cell lysis, cells cultured on the plate and treated with free DOX and CTX-PEG-G4.5DOX conjugates were washed twice with ice cold 1X DPBS buffer and then lysed on ice for 10
minutes using 110 µl of cell lysis buffer (20 mM HEPES, pH 7.5, 10 mM EGTA, pH 8.0, 40 mM
β-glycerophosphate, 1% NP-40, 2.5 mM MgCl2, 20 µg/ml aprotinin, 20 µg/ml leupeptin, 1 mM
PMSF). Cells were immediately scraped and transferred to sterile 1.5 ml microcentrifuge tubes.
The microcentrifuge tubes were centrifuged for 10 minutes at 12,000 rpm at 4°C. 5 µl of the
supernatant was transferred to fresh microcentrifuge tube containing 795 µl of DI water and 200
µl of Bio-Rad blue dye. This mixture was transferred to disposable cuvette the absorbance of
protein was measured on a Beckman Coulter DU® 640 Spectrophotometer at 600 nm. A mixture
of 800 µl of DI water and 200 µl of Bio-Rad blue dye was used as blank. The protein content
was quantified using a modified Bradford assay (BCA; Biorad, Hercules, CA). The amount of
DOX taken up by the cells was quantified using a Cary Eclipse Fluorescence spectrophotometer
with an excitation wavelength of 480 nm and an emission wavelength of 585 nm.
3.4.10 Statistical analysis
Statistical analysis was performed on anisotropy, hydrodynamic radius, zeta potential, and
cytotoxicity studies. All the statistical analysis was based on one way analysis of variance
(ANOVA: Single Factor) and Tukey’s test on SigmaPlot software. A p-value less than 0.05 was
considered statistically significant for rejecting the null hypothesis. Recording and analysis of
data and its graphical representation were done in Microsoft Excel 2007, where the error bars
represent standard deviations.
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CHAPTER 4 RESULTS AND DISCUSSION
4.1 Preparation and characterization of mal-PEG-G4.5
Bi-functional mal-PEG-NH2 was conjugated to G4.5 based on EDC/NHS chemistry. 20% of
carboxyl surface groups of G4.5 were activated using EDC with NHS. The amine group is highly
reactive towards activated carboxyl. Activated carboxyl and amine groups form an amide linkage
between mal-PEG and G4.5.
The conjugation of mal-PEG and G4.5 was confirmed by 1H-NMR. In the 1H-NMR of malPEG-G4.5 conjugate (Figure 4.1), the methylene proton peak of PEG (δ 3.69 ppm), multiple
proton peaks of G4.5 (δ 2.19-3.47 ppm) and maleimide proton peak of PEG (δ 6.69 ppm, very
dim signal) indicated the success of the synthesis of PEGylated dendrimer conjugates.
Corresponding peak area was integrated to determine the number of PEG molecules per G4.5
and hence approximate molecular weight of mal-PEG-G4.5 conjugate was calculated (Yang et
al., 2006). It was determined that an average of 1.6 PEG chains was coupled to every G4.5
molecule. The approximate molecular weight of mal-PEG-G4.5 conjugate was calculated to be
31,858 g/mol.
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Figure 4.1 1H-NMR spectrum of mal-PEG-G4.5
4.2 Preparation and characterization of mal-PEG-G4.5-DOX
Hydrazon groups were attached to the G4.5 dendrimer via an acid anhydride reaction as
mentioned in Figure 3.2 (Bae et al., 2003; Lai et al., 2007). Synthesized mal-PEG-G4.5-HydBOC was treated with trifluoro acetic acid (TFA) to remove the BOC protective groups. DOX
was then attached to the hydrazon residues of the mal-PEG-G4.5-Hyd through an imine, the
Schiff base bond as mentioned in Figure 3.2 (Bae et al., 2003; Lai et al., 2007). The formed malPEG-G4.5-DOX was dialyzed with PBS (pH 7.4) and applied to a PD-10 column for further
purification.
The conjugation of DOX to mal-PEG-G4.5-Hyd was confirmed using fluorescence
anisotropy. Fluorescence anisotropy is measure of the fluorescence depolarization of fluorescent
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molecules (Ingersoll et al., 2007; Lakowicz et al., 2006). Since fluorescence depolarization is
caused by rotational diffusion of the fluorophore during its excited lifetime, the rotational
mobility of the fluorophore can be determined with the help of anisotropy, r. If a molecule is
freely suspended, it will have a faster rotational diffusion, thus a lower anisotropy value. Thus if
it is bound to a large molecule, the rotational diffusion of the fluorophore will decrease and thus
anisotropy should increase (Ingersoll et al., 2007). DOX is a fluorophore with an excitation
wavelength at 480 nm and an emission wavelength at 585 nm in methanol. The anisotropy of
free DOX was found to be 0.032 ± 0.001. The anisotropy value increased by 60% to 0.054 ±
0.002 for DOX-G4.5-PEG-mal (n=6, with each run having 800 internal averages). The increased
anisotropy was attributed to the conjugation of DOX to a large molecule mal-PEG-G4.5 (MW =
31,858) and hence confirmed the conjugation of PEGylated dendrimer to doxorubicin.
Significant statistical difference was found between the two anisotropy values with p<0.05.
The amount of DOX attached to PEGylated dendrimer was calculated using UV-Vis
spectroscopy. 1.7 mg/ ml of DOX-G4.5-PEG-mal in 1X-PBS gave an absorbance of 0.666 (n=3)
and according to the standard curve of doxorubicin (Figure 3.5) the concentration of DOX in this
sample was calculated using Eq. 4 and Eq. 5 to be 0.277 mg/ml or 0.479 µmol/ml. Using the
molecular weight of mal-PEG-G4.5 as 31,858 g/mol, calculated earlier, their number of mole in
the 1.7 mg/ml sample were calculated using Eq. 6 and Eq. 7 and were found to be 0.045
µmol/ml. Using Eq. 8, it was calculated that approximately 10.7 molecules of DOX were
attached per G4.5-PEG-mal molecule.
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4.3 Preparation and characterization of CTX-PEG-G4.5-DOX
EGFR is over-expressed in more than 35% of all solid malignant tumors (Salomon et al.,
1995) but is very weakly expressed and almost undetectable in the normal brain (Sauter et al.,
1996; Schwechheimer et al., 1995). This makes the EGFR an attractive option for targeted
delivery of therapeutics to gliomas. Liposomes and PLA micelles have been conjugated with
CTX for EGFR selective targeting previously (Pan et al., 2007; Liu et al., 2009). Anti-EGFR
monoclonal antibody CTX was assembled on the G4.5 surface via PEG spacer. Thiolated CTX
(Pan et al., 2007; Liao et al., 2010) have proved to be efficient in coupling with maleimidebearing polymer. As thiolation happens on the carbonate part of the Fc portion, the EGF receptor
recognizing ability of CTX is preserved (Pan et al., 2007). CTX was first thiolated with Traut’s
reagent (2-iminothiolane, Marsh et al., 1988) (Pan et al., 2007; Huwyler et al., 1996). An
optimum 2-iminothiolane/ CTX molar ratio of 40:1 was used which on an average yields
thiolation of one primary amine per CTX (Huwyler et al., 1996). The thiolated CTX to
maleimide molar ratio was kept at 2:1 to yield an average of one CTX molecule per mal-PEGG4.5-DOX molecule. Success of conjugation of CTX to maleimide bearing dendrimer via PEG
linker was confirmed using Western blotting (Figure 4.2). Using Western blot, the molecular
weight of CTX-PEG-G4.5-DOX was calculated to be around 190 kDa. This molecular weight
indicated that on an average, 1 CTX was conjugated to mal-PEG-G4.5-DOX. Using the
molecular weights (CTX 150kDa, mal-PEG-NH2 3500 Da, G4.5 26258 Da and DOX 580 g) and
molar ratios (CTX:PEG: G4.5: DOX as 1:1.6:1:10.7) mathematically the molecular weight of
CTX-PEG-G4.5-DOX molecule comes out to be 188 kDa, which is equivalent to that indicated
by Western blot.
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190 kDa
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Figure 4.2 Western blot of CTX-PEG-G4.5-DOX (lane 1) and free CTX (lane 2)

4.4 Particle size and zeta potential
Dynamic light scattering (DLS) was used to determine the particle size and zeta potential of
the conjugates. The reaction chemistry involves multiple reactions and different types of
functional moieties, which can lead to undesired cross-reactions. To avoid these unwanted
reactions, CTX-PEG-G4.5-DOX conjugate was developed based on a 3-step layer-by-layer
design. The first layer composed of mal-PEG conjugated to dendrimer. The second layer
consisted of conjugation of DOX on the G4.5 surface. The third functional layer of CTX was
assembled on the G4.5 surface via the PEG spacer attached earlier. The hydrodynamic size and
zeta potential determined from DLS are summarized in Table 4.1. Coupling of different moieties
to the G4.5 surface resulted in a consecutive increase in size and change in zeta potential. The
success of the surface modifications is clearly reflected by the changes of size and zeta potential.
The size of G4.5 was found to be 3.24 ± 0.46 nm which increased to 5.63 ± 0.23 nm with the
addition of mal-PEG on its surface. mal-PEG-G4.5-DOX showed a measurable size of 39.78 ±
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0.37 nm, a 12-fold increase after the addition of DOX as compared to G4.5. This significant
increase in size can be linked with the addition of mal-PEG and DOX on the dendrimer surface
and also can be attributed to flocculation of particles due to mal-PEG chain entanglement. As the
surface of G4.5 was modified, the zeta potential changed from -21.02 ± 0.35 mV for G4.5 to 2.53 ± 0.16 mV for mal-PEG-G4.5-DOX. All the conjugate groups showed significant statistical
difference with each other with p<0.05.
Table 4.1 Size and zeta potential of the tested conjugates in pH 7.4 PBS at 37°C
Conjugates

Size (nm, n=10) (p<0.05)

Zeta Potential (mV, n=10) (p<0.05)

G4.5

3.24 ± 0.46

-21.02 ± 0.35

mal-PEG-G4.5

5.63 ± 0.23

-18.08 ± 0.95

mal-PEG-G4.5-DOX

39.78 ± 0.37

-2.53 ± 0.16

4.5 Release kinetics of DOX
Enhanced permeability and retention effect (EPR) plays an important role in tumor targeting
in body (Maeda et al., 1989). Macromolecules are engulfed by the cells via endocytosis (Bae et
al., 2003). The endocytic pathway undergoes a pH change from 7.4 to 4.5 (Zhu et al., 2010).
Release of DOX can be triggered by low pHs. DOX released from DOX-G4.5-PEG-CTX
conjugates was measured at different pHs to evaluate the pH sensitivity of the hydrazon linkage
between G4.5 and DOX. The pH values of the buffers were chosen as 7.4 (normal blood), 5.5
and 4.5 (endosomal/lysosomal pH) for DOX release. As shown in Figure 4.3, DOX released
from DOX-G4.5-PEG-CTX was pH dependent. Less than 20% of DOX was released at pH 7.4
over a period of 192 hours, indicating that DOX-G4.5-PEG-CTX conjugates would be stable in
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the blood stream. At pH 5.5 a total of 30% drug was released in 192 hours, whereas almost 90%
of the DOX conjugated to G4.5 released in 192 hours at pH 4.5. This proved the success of
attaching DOX via an acid liable linkage to G4.5 dendrimer. DOX is sensitive to light,
temperature, ph and solvent used. DOX is more stable in acidic medium (pH 7.4 to pH 4.5) with
maximum stability at pH 4. Although immense care was taken to conduct the experiment in dark,
there was still some exposure to light, and higher pH of 7.4 led to photo-degradation of DOX
after 192 hours, which turned it to a deep blue-purple compound. Due to this photo-degradation,
the release kinetics studies were stopped at 192 hours. Huge standard deviation observed for pH
4.5 at 192 hours can also be attributed to this photo-degradation. Statistical analysis showed
significant difference between pH 4.5 vs. pH 5.5 and pH 4.5 vs. pH 7.4 (p<0.05), where as there
was no significant statistical difference between pH 5.5 and pH 7.4.

Figure 4.3 Cumulative release profiles of DOX from CTX-PEG-G4.5-DOX conjugates at
different pH
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4.6 Cytotoxicity studies
HN12 cells were used to perform cytotoxicity tests. Untreated HN12 cells were used as a
positive control. The cells were incubated with DOX-G4.5-PEG-CTX or free DOX at DOX
equivalent concentration of 100, 10 and 1 nmol (higher concentrations such as 1 and 10 µmol
were highly cytotoxic with 0% cells viable after 24 hours). The amount of DOX-G4.5-PEG-CTX
equivalent to free DOX also contained CTX at a concentration of 10, 1 and 0.1 nmol, thus cells
were also incubated with equivalent free CTX concentration. The cytotoxicity was both dose and
time dependent. As seen in Figure 4.4, DOX-G4.5-PEG-CTX conjugate was cytotoxic at all
concentrations. A constant reduction in the activity of cells was indicated by Trypan blue test
over a period of 72 hours (n=6), which indicated a controlled release of DOX from the
nanoparticles which was also seen in the DOX release studies. There was no significant
statistical difference within the groups over 72 hours except groups N1, D1, CTX1 and CTX0.1
(p<0.05). When individual concentrations were compared, it was observed that the cytotoxicity
of DOX-G4.5-PEG-CTX was much higher than that of the equivalent amount of free CTX. This
increased cytotoxicity can be attributed to a combined effect of DOX and CTX as reported
earlier (Vega et al., 2003; Liao et al., 2010). However, the cytotoxicity of DOX-G4.5-PEG-CTX
was relatively less or equal to free DOX. This can be a result of the presence of biocompatible
PEG in the dendrimer conjugates. Significant statistical difference was observed with all groups
compared as whole with p<0.05.
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Figure 4.4 Cytotoxicity studies of DOX-G4.5-PEG-CTX (N), free DOX (D) and free CTX at
different equivalent concentration of DOX and CTX. (N100, N10, N1: DOX-G4.5-PEG-CTX at
DOX equivalent concentration of 100, 10 and 1 nmol; D100, D10, D1: free DOX at
concentration of 100, 10 and 1 nmol; CTX10, CTX1, CTX0.1: free cetuximab at DOX-G4.5PEG-CTX equivalent concentration of 10, 1 and 0.1 nmol)

4.7 Cellular uptake studies
Fluorescence microscopy was performed to investigate the mechanism behind free DOX and
CTX-PEG-G4.5-DOX uptake in the HN12 cells. It was found that free DOX translocated from
cytosol to the nucleus after 6 hours incubation as seen in Figure 4.5. It has been reported earlier
that DOX penetrates the plasma and then diffuses into the nucleus, where it interacts with the
DNA (Alton et al., 1998). On the other hand, after 6 hours of incubation, CTX-PEG-G4.5-DOX
was present both in the cytosol and the nucleus. Cells internalize macromolecules via
endocytosis. Endosomes have an acidic pH 6 due to the proton pump present on the membrane.
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When these endosomes change from early endosomes to late endosomes, their internal pH goes
further down to pH 5.5 (Cooper et al., 1977). The hydrazon linkage between the DOX and G4.5PEG-CTX should start breaking in the early and late endosomes stage inducing death signals in
the cells (Rihova et al., 2002). Golgi apparatus releases transport vesicles which carry lysosomal
hydrolases, which fuse with late endosomes to form lysosomes. The lysosomes are much more
acidic with pH 4.5-pH 5 which would result in more release of DOX bound to the G4.5-PEGCTX conjugate and resulted in cell death as shown in cell viability. The cellular uptake results
are similar to results found in earlier studies done with similar linkage of DOX with other
polymers like HPMA (Etrych et al., 2002; Rihova et al., 2001), PEG (Rodrigues et al., 1999),
and neuropeptide (Langer et al., 2001). The amount of free DOX and DOX-G4.5-PEG-CTX
uptaken by the cells was found out using cell lysis studies. As seen in Figure 4.5 B and E,
although equivalent concentrations of DOX were used still the intensity of DOX is much lower
in cells treated with free DOX (Figure 4.5–B) to those treated with DOX-G4.5-PEG-CTX
conjugates (Figure 4.5-E). It was found that after 6 hour incubation the uptake of DOX-G4.5PEG-CTX was ten-folds higher at 2.32 nmols/ µg of protein as compared to that of free DOX at
0.25 nmols/ µg of protein, suggesting CTX facilitates particle uptake via receptor mediated
endocytosis.
4.8 Conclusion
A tumor-targeted dendrimer-based delivery system carrying CNS drugs was synthesized
through a 3-step layer-by-layer design mechanism. Chemotherapy drug doxorubicin was
successfully conjugated to the dendrimer via acid-liable hydrazon linker. Monoclonal antibody
cetuximab was successfully conjugated to the dendrimer via PEG linker as the targeting ligand.
The conjugate was characterized with NMR, fluorescence anisotropy, UV-Vis, DLS, zeta
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potential and Western blotting. A controlled release of DOX was observed at pH 4.5. The
dendrimer conjugate was very stable at bloodstream pH of 7.4. Cytotoxicity of the dendrimer
conjugate was considerably high compared to free cetuximab but was lower than free
doxorubicin because of the addition of PEG chains.

A

B

C

D

E

F

Figure 4.5 Cellular uptake of free DOX (A: Nucleus with DAPI, B: free DOX in nucleus, C:
overlapped nucleus and free DOX) and DOX-G4.5-PEG-CTX (D: Nucleus with DAPI, E: DOX
from DOX-G4.5-PEG-CTX, F: overlapped nucleus and DOX from DOX-G4.5-PEG-CTX)
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CHAPTER 5 SUMMARY AND FUTURE WORK
Synthetic polymers coupled with anticancer drugs can increase the efficacy and reduce the sideeffects of such drugs (Lai et al., 2007). Polymers can be easily modified as potent drug delivery
systems. We designed a brain-targeted drug delivery system for high EGFR expressing tumors.
We demonstrated the change in size and surface properties due to addition of functional moieties
to dendrimers. Considering endocytic release of drug, we demonstrated pH sensitive drug release
of doxorubicin; various other drugs can be incorporated in a similar way for future testing.
Different protein assays can be used to characterize monoclonal antibody. All the studies done in
this work were using cancer cells, further analysis can be done using in vitro BBB model.
Further studies can be done to determine if the drug delivery system can be administered using
an alternative drug administration route. BBB administration can be evaluated using only Fab’
fragments of the antibody as evaluated in an earlier work (Mamot et al., 2005).
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Interpretation of the statistical analysis shown in Appendix A, B, C, D and E
Analysis of Variance (ANOVA):


p < 0.05 indicates that the data is statistically significant

Tukey’s Pairwise Comparisons:


Performed to determine statistical difference between two data values



Confidence interval (lower to upper) excludes zero : significant statistical difference
between data values



Confidence interval (lower to upper) includes zero : insignificant statistical difference
between data values
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Appendix A (Statistical data for anisotropy)
One Way Analysis of Variance (ANOVA): Anisotropy
Data source: Data 1 in Notebook1
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
r for DOX-G4.5-PEG
r for free DOX
Source of Variation
Between Groups
Residual
Total

Passed (P = 0.598)

Passed (P = 0.758)
N
6
6

Missing
0
0
DF
1
10
11

Mean
0.0538
0.0323

SS
0.00139
0.0000222
0.00141

Std Dev
0.00160
0.00137
MS
0.00139
0.00000222

SEM
0.000654
0.000558
F
625.602

P
<0.001

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = <0.001).
Power of performed test with alpha = 0.050: 1.000

All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison
Diff of Means
r for DOX-G4.5-PEG vs. r for free D
0.0215

t
25.012
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P
<0.001

P<0.050
Yes

Appendix B (Statistical data for hydrodynamic size)
One Way Analysis of Variance (ANOVA) : Particle size
Data source: Data 1 in Notebook2
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 1 in Notebook2
Group

N

Missing

Median

25%

75%

G4.5 (nm)

10

0

3.529

2.780

3.615

mal-PEG-G4.5 (nm)

10

0

5.606

5.523

5.828

mal-PEG-G4.5-DOX (nm) 10

0

39.680

39.432

40.140

H = 25.812 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison

Diff of Ranks

q

P<0.05

mal-PEG-G4.5-DOX vs G4.5 (nm)

200.000

7.184

Yes

mal-PEG-G4.5-DOX vs mal-PEG-G4.5

100.000

3.592

Yes

mal-PEG-G4.5 (nm) vs G4.5 (nm)

100.000

3.592

Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.

62

Appendix C (Statistical data for zeta potential)
One Way Analysis of Variance
Data source: Data 1 in Notebook2
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 1 in Notebook2
Group
G4.5 (mV)
mal-PEG-G4.5 (mV)
mal-PEG-G4.5-DOX (mV)

N
10
10
10

Missing
0
0
0

Median
-21.100
-18.650
-2.595

25%
-21.225
-18.800
-2.612

75%
-20.875
-17.275
-2.543

H = 25.864 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.

All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
Diff of Ranks
mal-PEG-G4.5-DOX vs G4.5 (mV)
200.000
mal-PEG-G4.5-DOX vs mal-PEG-G4.5
100.000
mal-PEG-G4.5 (mV) vs G4.5 (mV)
100.000

q
7.184
3.592
3.592

P<0.05
Yes
Yes
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.
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Appendix D (Statistical data for cumulative release kinetics of DOX)

One Way Analysis of Variance

(ANOVA): Cumulative release kinetics of DOX

Data source: Data 1 in Release kinetics.JNB
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 1 in Release kinetics.JNB
Group

N

Missing

Median

25%

75%

pH 7.5

12

0

15.350

13.500

18.300

pH 5.5

12

0

19.600

14.225

29.400

pH 4.5

12

0

40.227

33.815

53.149

H = 22.677 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison

Diff of Ranks

q

P<0.05

pH 4.5 vs pH 7.5

237.500

6.507

Yes

pH 4.5 vs pH 5.5

173.500

4.754

Yes

pH 5.5 vs pH 7.5

64.000

1.754

No

Note: The multiple comparisons on ranks do not include an adjustment for ties.
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Appendix E (Statistical data for cytotoxicity assay)
One Way Analysis of Variance
Data source: Data 1 in Notebook3
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 1 in Notebook3
Group
N100
N10
N1
D100
D10
D1
CTX10
CTX1
CTX0.1

N
9
9
9
9
9
9
9
9
9

Missing
0
0
0
0
0
0
0
0
0

Median
131000.000
260000.000
229000.000
173000.000
169000.000
208000.000
309000.000
347000.000
329000.000

25%
106000.000
204000.000
204000.000
143000.000
133500.000
129500.000
220000.000
253500.000
247500.000

75%
175500.000
325000.000
436500.000
219500.000
270500.000
307500.000
429500.000
415500.000
485500.000

H = 30.710 with 8 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.

All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
Diff of Ranks
CTX0.1 vs N100
406.000
CTX0.1 vs D10
286.500
CTX0.1 vs D100
286.000
CTX0.1 vs D1
218.500
CTX0.1 vs N10
140.500
CTX0.1 vs N1
109.000
CTX0.1 vs CTX10
52.500
CTX0.1 vs CTX1
26.500
CTX1 vs N100
379.500
CTX1 vs D10
260.000
CTX1 vs D100
259.500
CTX1 vs D1
192.000
CTX1 vs N10
114.000
CTX1 vs N1
82.500
CTX1 vs CTX10
26.000
CTX10 vs N100
353.500
CTX10 vs D10
234.000
CTX10 vs D100
233.500
CTX10 vs D1
166.000

q
5.752
4.059
4.052
3.096
1.991
1.544
0.744
0.375
5.377
3.684
3.677
2.720
1.615
1.169
0.368
5.009
3.315
3.308
2.352

P<0.05
Yes
No
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Yes
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Yes
Do Not Test
Do Not Test
Do Not Test
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CTX10 vs N10
CTX10 vs N1
N1 vs N100
N1 vs D10
N1 vs D100
N1 vs D1
N1 vs N10
N10 vs N100
N10 vs D10
N10 vs D100
N10 vs D1
D1 vs N100
D1 vs D10
D1 vs D100
D100 vs N100
D100 vs D10
D10 vs N100

88.000
56.500
297.000
177.500
177.000
109.500
31.500
265.500
146.000
145.500
78.000
187.500
68.000
67.500
120.000
0.500
119.500

1.247
0.801
4.208
2.515
2.508
1.551
0.446
3.762
2.069
2.061
1.105
2.657
0.963
0.956
1.700
0.00708
1.693

Do Not Test
Do Not Test
No
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test

Note: The multiple comparisons on ranks do not include an adjustment for ties.
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank
sums that enclose that comparison. For example, if you had four rank sums sorted in order, and found no significant
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1). Note that not testing the enclosed rank sums is a procedural rule,
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even
though one may appear to exist.
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Appendix F (Properties and handling of DOX)
General Details
Approved name: Doxorubicin, Doxorubicin Hydrochloride
Derivation: Strptomyces peucetius var. caesius
Proprietary name: Adriamycin
Diseases: Hematological malignancies, Carcinoma, Soft tissue sarcomas, Metastatic endometrial
cancer and advanced ovarian cancer
Dissolution: Sterile, pyrogen-free, orange-red, freeze dried powder
Storage and shelf life:
 Light Sensitive
 Dry, unopened: Dry place away from light, Three years
 Solution: 2 to 8 ˚C, Eighteen months
 Removed from refrigeration: One Month
Chemistry
Type: Cytotoxic antibody containing
 An aminosugar, daunosamine
 Gylcosidic bond to C7
 Tetracyclic aglycone, doxorubicinone
Action
 Complex with DNA
 Interferes nucleic acid synthesis
 Highest activity : S phase
Molecular Study
Molecular structure
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Molecular Weight: 580.0
Solubility
 Water
 5% Glucose
 0.9% Sodium Chloride
 Partially in Alcohol
Insoluble
 Chloroform, ether, other organic solvents
Stability Profile
Physical and chemical stability
 48 hours at room temperature in normal artificial light
 18 months at 2-8˚C at pH 3.0
 One month at room temperature at pH 3.0
Stability depends
 Temperature
 pH
 Solvent
Light sensitive
Absorbs on to glass and certain plastics
Effect of pH
More stable in acidic medium (pH 7.4 to pH 4.5)
 Maximum at pH 4.0
Below pH 4.0
 Acidic hydrolysis – red-colored, water insoluble aglycone and water-soluble amino sugar
 Rate proportional to hydrogen ion concentration
 Aglycone is inactive
 Dependent on structural modification in amino sugar
Above pH 4.0
 Color change from red to deep blue-purple
 Rapid degradation occurs
 At pH 8.0, fluorescing compounds
pH ≤ 9.5
 Accelerated by acetate, phosphate and carbonate buffers
pH > 10.0
 No buffer catalysis
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Alkaline solution
 Anthracyclines are affected by structural modification of aglycone portion of the
molecule
Photodegradation
Substantial photodegradation observed at concentrations below 100 µg/ml.
No special precautions are needed at Concentrations ≥ 500 µg/ml
Effect of Temperature
Stability
 Water, concentration 2 mg/ml, 4˚C polypropylene syringe, 6 months
 25 ˚C in dark
o 5% glucose, pH 4.7
o 3.3% glucose with 0.3% sodium chloride, pH 4.4
o Polypropylene tubes for 28 days
o Significant degradation in six days in 0.9% sodium chloride, pH 7.0
 PVC minibags
o 0.9% sodium chloride, pH 6.7 at 25 ˚C in dark
o Loss in potency
o 5% glucose, pH 4.36 and 0.9% sodium chloride (pH 5.2 and pH 6.47), 43 days at
4˚C
 Freezing Doxorubicin
o 2 mg/ml aqueous solution, one month, -20 ˚C
o Cannot be frozen with sodium chloride
o 5% glucose, pH 4.36 and 0.9% sodium chloride (pH 5.2 and pH 6.47), 43 days at
-20˚C
 Microwave Radiation
o Concentration reduces after four re-thawing in microwave
o Stable for 2 weeks thawed by any means
o Aqueous solutions frozen and thawed seven times
o Overheating may lead to degradation
o Thawing in microwave NOT RECOMMENDED
Container Compatibility
Polypropylene, polyethylene, PVC and glass
More stable in plastics than glass
Absorbs on to glass and polyethylene
Diluted solutions absorb more on membranes
Negligible absorbance at concentrations of at least 500 µg/ml
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Compatibility with other drugs
Incompatible
 Heparin, dexamethasome sodium phosphate, hydrocortisone sodium succinate and
diazepam
 Combination with fluorouracil or aminophylline resuls in color change
Compatible in
 Vincristine, but with buffer
 Recommended NOT to be mixed with any drug
Destruction
Incineration – 700 ˚C
Chemical
 Dilute sodium hypochlorite for 24 hours
Contact with skin
 Wash with water, soap or sodium bicarbonate solution
Contact with eyes
 Irrigation with saline
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Appendix G (Gravity protocol of PD-10 column)
(Based on GE Healthcare, Instructions 52-1308-00 BB)
PD-10 properties


SephadexTM G-25 medium



Uses: Desalting, buffer exchange and removal of low-molecular weight impurities



Particle size range: 85-260 µm



Bed dimention: 1.45 x 5.0 cm, 8.3 ml



Exclusion limit: 5000



Chemical stability: All common buffers



Working pH: 2-13



Storage temperature: +4 to +30˚C



Storage solution: 0.15% Kathon CG/ICP Biocide

Protocols


Gravity protocol



Spin protocol

Properties

Gravity protocol

Spin protocol

Description

Use of Gravity force

Additional force by spinning
in centrifuge

Higher recovery
No dilution of sample
Applied sample is diluted
Sample volume

1.0-2.5 ml

1.75-2.5 ml

Elution buffer

3.5 ml

None

Dilution factor

1.4 times

None

Desalting capacity

>98%

>90%
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Gravity protocol
1. Remove the top cap and discard the column storage solution
2. Cut the seal at the end of column using scissors
3. Fix the column secure on burette stand
4. Take 25 ml of equilibration buffer equilibrate column up to four times
a. Fill column with buffer and let the bed be completely soaked.
b. Discard the flow-through buffer
5. Add 2.5 ml of sample
a. If sample is lesser than 2.5, after the sample is completely soaked in column, add
equilibration buffer to adjust the volume to 2.5 ml
b. Discard the flow through
6. Use 3.5 ml of buffer to elute samples
7. Place microcentrifuge tubes below the column to collect samples at fixed time intervals
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